Crohn’s disease (CD) and ulcerative colitis (UC) are caused by the over-activity of the immune system. Current and novel therapies are designed to dampen these over-active responses. Analysis of the types of immune responses ongoing in diseased mucosa of inflammatory bowel disease patients has revealed that CD and UC are fundamentally different diseases. The former has the molecular imprints of a Th1 dominant cell-mediated hypersensitivity response whereas the latter appears to involve antibody-mediated hypersensitivity.
- Crohns Disease
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Lamina Propria
- Crohns Disease Patient
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Unable to display preview. Download preview PDF.
James SP. Remission of Crohn’s disease after human immunodeficiency virus infection. Gastroenterology 1988; 95:1667–1669.
Mullin GE, Lazenby AJ, Harris ML et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn’s disease but not ulcerative colitis. Gastroenterology 1992; 102:1620–1627.
Breese E, Braegger CP, Corrigan CJ et al. Interleukin-2-and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78:127–131.
Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261–1270.
Monteleone G, Biancone L, Marasco R et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112:1169–1178.
Parronchi P, Romagnani P, Annunziato F et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn’s disease. Am J Pathol 1997; 150:823–832.
Parrello T, Monteleone G, Cucchiara S et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohn’s disease. J Immunol 2000; 165:7234–7239.
Monteleone G, Trapasso F, Parrello T et al. Bioactive IL-18 expression is up-regulated in Crohn’s disease. J Immunol 1999; 163:143–147.
Pizarro TT, Michie MH, Bentz M et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: Expression and localization in intestinal mucosal cells. J Immunol 1999; 162:6829–6835.
Avni O, Lee D, Macian F et al. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002; 3:643–651.
Szabo SJ, Kim ST, Costa GL et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655–669.
Mullen AC, Hutchins AS, High FA et al. Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat Immunol 2002; 3:652–658.
Afkarian M, Sedy JR, Yang J et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 2002; 3:549–557.
Lighvani AA, Frucht DM, Jankovic D et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001; 98:15137–15142.
Neurath MF, Weigmann B, Finotto S et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med 2002; 195:1129–1143.
Shanahan F. Crohn’s disease. Lancet 2002; 359:62–69.
Duchmann R, Kaiser I, Hermann E et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448–455.
Winkelstein JA, Marino MC, Johnston Jr RB et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155–169.
Myrup B, Valerius NH, Mortensen PB. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 1998; 42:127–130.
Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411:603–606.
Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411:599–603.
Pflanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16:779–790.
Christ AD, Stevens AC, Koeppen H et al. An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn’s disease. Gastroenterology 1998; 115:307–313.
Omata F, Birkenbach M, Matsuzaki S et al. The expression of IL-12 p40 and its homologue, Epstein-Barr virus-induced gene 3, in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7:215–220.
Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn’s disease of the colon. Gastroenterology 1987; 93:919–924.
Brandtzaeg P. The B cell system. Food Allergy & Intolerance. London: Bailliere Tindall, 1987; 118–155.
Mee AS, McLaughlin JE, Hodgson HJ et al. Chronic immune colitis in rabbits. Gut 1979; 20:1–5.
Halstensen TS, Mollnes TE, Garred P et al. Surface epithelium related activation of complement differs in Crohn’s disease and ulcerative colitis. Gut 1992; 33:902–908.
Halstensen TS, Mollnes TE, Garred P et al. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990; 98:1264–1271.
Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the M(r) 40 kD putative autoantigen in ulcerative colitis. Gut 1993; 34:650–657.
McGiven AR, Ghose T, Nairn RC. Autoantibodies in ulcerative colitis. Br Med J 1967; 2:19–23.
Marcussen H, Nerup J. Fluorescent anti-colon and organ-specific antibodies in ulcerative colitis. Scand J Gastroenterol 1973; 8:9–15.
Rutgeerts P, D’Haens G, Hiele M et al. Appendectomy protects against ulcerative colitis. Gastroenterology 1994; 106:1251–1253.
Shanahan F, O’Sullivan GC. Appendectomy, mucosal immunity, and colitis. Gastroenterology 1997; 112:1766–1767.
Okazaki K, Onodera H, Watanabe N et al. A patient with improvement of ulcerative colitis after appendectomy. Gastroenterology 2000; 119:502–506.
Cosnes J, Carbonnel F, Beaugerie L et al. Effects of appendectomy on the course of ulcerative colitis. Gut 2002; 51:803–807.
Pospisil R, Mage RG. Rabbit appendix: A site of development and selection of the B cell repertoire. Curr Top Microbiol Immunol 1998; 229:59–70.
Reynolds JD, Kennedy L, Reppard J et al. Ileal Peyer’s patch emigrants are predominantly B cells and travel to all lymphoid tissues in sheep. Eur J Immunol 1991; 21:283–289.
Thoree VC, Golby SJ, Boursier L et al. Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitis. Gut 2002; 51:44–50.
van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002; 50(Suppl 3):III47–III53.
MacDonald TT, Pender SL. Proteolytic enzymes in inflammatory bowel disease. Inflamm Bowel Dis 1998; 4:157–164.
Saarialho-Kere UK, Vaalamo M, Puolakkainen P et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996; 148:519–526.
Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998; 152:1005–1014.
Pender SL, Breese EJ, Gunther U et al. Suppression of T cell-mediated injury in human gut by interleukin 10: Role of matrix metalloproteinases. Gastroenterology 1998; 115:573–583.
Heuschkel RB, MacDonald TT, Monteleone G et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000; 47:57–62.
Pender SL, Tickle SP, Docherty AJ et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158:1582–1590.
Monteleone G, MacDonald TT, Wathen NC et al. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 1999; 117:1069–1077.
Lukashev ME, Werb Z. ECM signalling: Orchestrating cell behaviour and misbehaviour. Trends Cell Biol 1998; 437–41.
Imai K, Hiramatsu A, Fukushima D et al. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997; 322:809–14.
Uria JA, Jimenez MG, Balbin M et al. Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem 1998; 273:9769–9777.
Monteleone G, Kumberova A, Croft NM et al. Blocking Smad7 restores TGFα1 signalling in chronic inflammatory bowel disease. J Clin Invest 2001; 108:601–608.
Lochter A, Galosy S, Muschler J et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997; 139:1861–72.
Noe V, Fingleton B, Jacobs K et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114:111–118.
Berx G, Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14:6107–15.
Roghani M, Becherer JD, Moss ML et al. Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic activity. J Biol Chem 1999; 274:3531–40.
Ito A, Mukaiyama A, Itoh Y et al. Degradation of interleukin 1α by matrix metalloproteinases. J Biol Chem 1996; 271:14657–60.
Shull MM, Ormsby I, Kier AB et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359:693–699.
Kulkarni AB, Huh CG, Becker D et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90:770–774.
Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110:975–984.
Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002; 296:1646–1647.
Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J Cell Sci 2001; 114:4359–4369.
Monteleone G, Mann J, Monteleone I et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappa B activation in gut inflammation. J Biol Chem. 2004; 279:3925–3932.
Tahkalidis P et al. Microscopic colitis. J Gastro Hepatol 17:236–248.
Lazenby AJ, Yardley JH, Giardiello FM et al. Lymphocytic (“microscopic”) colitis: A comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol 1989; 20:18–28.
Mosnier JF, Larvol L, Barge J et al. Lymphocytic and collagenous colitis: An immunohistochemical study. Am J Gastroenterol 1996; 91:709–713.
Gunther U, Schuppan D, Bauer M et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and-13, and TIMP-1 gene expression. Am J Pathol 1999; 155:493–503.
Miehlke S, Heymer P, Bethke B et al. Budesonide treatment for collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002; 123:978–984.
Editors and Affiliations
© 2006 Eurekah.com and Springer Science+Business Media
About this chapter
Cite this chapter
MacDonald, T.T., Monteleone, G. (2006). Overview of Role of the Immune System in the Pathogenesis of Inflammatory Bowel Disease. In: Blumberg, R.S., Neurath, M.F. (eds) Immune Mechanisms in Inflammatory Bowel Disease. Advances in Experimental Medicine and Biology, vol 579. Springer, New York, NY. https://doi.org/10.1007/0-387-33778-4_6
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-30831-9
Online ISBN: 978-0-387-33778-4